Revance Therapeutics Inc. (NASDAQ:RVNC) shares rose 5.5% during trading on Wednesday . The company traded as high as $16.40 and last traded at $16.37, with a volume of 106,963 shares trading hands. The stock had previously closed at $15.51.

RVNC has been the subject of a number of analyst reports. Guggenheim reaffirmed a “buy” rating and issued a $55.00 price target on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Brean Capital reaffirmed a “buy” rating on shares of Revance Therapeutics in a research note on Saturday, June 4th. SunTrust Banks Inc. dropped their price target on Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, June 14th. Zacks Investment Research raised Revance Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Wednesday, July 13th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $35.00 price target (down previously from $54.00) on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Revance Therapeutics currently has a consensus rating of “Buy” and an average target price of $39.60.

The company has a 50-day moving average of $14.07 and a 200 day moving average of $16.70. The firm’s market capitalization is $405.61 million.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.02. The business earned $0.80 million during the quarter, compared to analysts’ expectations of $0.06 million. The firm’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts forecast that Revance Therapeutics Inc. will post ($3.53) EPS for the current year.

A hedge fund recently raised its stake in Revance Therapeutics stock. Schwab Charles Investment Management Inc. boosted its stake in Revance Therapeutics Inc. (NASDAQ:RVNC) by 35.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 63,467 shares of the biopharmaceutical company’s stock after buying an additional 16,625 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.23% of Revance Therapeutics worth $2,169,000 as of its most recent filing with the SEC.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.